Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Frontiers in Immunology|February 27, 2015
Distinct Transcriptomic Features are Associated with Transitional and Mature B-Cell Populations in the Mouse SpleenEden Kleiman, Daria Salyakina, Magali De Heusch, et al.
Frontiers in Immunology|July 27, 2016
Corrigendum: Distinct Transcriptomic Features Are Associated with Transitional and Mature B-Cell Populations in the Mouse SpleenEden Kleiman, Daria Salyakina, Magali De Heusch, et al.
Science Translational Medicine|August 23, 2023
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strainsLionel Sacconnay, Jonathan De Smedt, Vera Rocha-Perugini, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 TrialTino F Schwarz, Shinn-Jang Hwang, Pedro Ylisastigui, et al.
The Journal of Infectious Diseases|July 29, 2022
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical TrialIsabel Leroux-Roels, Matthew G Davis, Katie Steenackers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2024
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of AgeMurdo Ferguson, Tino F Schwarz, Sebastián A Núñez, et al.
The Journal of Infectious Diseases|February 1, 2023
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized TrialZourab Bebia, Osvaldo Reyes, Robert Jeanfreau, et al.
Pageof 2